drugset / Trial / NCT04562129
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Phase 2
Recruiting
29 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Clinigen, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
Timeline
- Start
- 2020-09-24
- Primary completion
- 2026-07
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 600000 iu/kg | Intravenous |